Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Retirement Guys Formula LLC

Retirement Guys Formula LLC boosted its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 55.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 63,817 shares of the company’s stock after buying an additional 22,660 shares during the period. Retirement Guys Formula LLC’s holdings in Galectin Therapeutics were worth $175,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock valued at $4,732,000 after purchasing an additional 38,037 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Galectin Therapeutics by 317.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock valued at $1,092,000 after purchasing an additional 367,610 shares in the last quarter. Wealthspire Advisors LLC raised its holdings in shares of Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after purchasing an additional 214,512 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Galectin Therapeutics in the 2nd quarter valued at $227,000. Finally, Squarepoint Ops LLC raised its holdings in shares of Galectin Therapeutics by 75.4% in the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock valued at $190,000 after purchasing an additional 36,139 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Trading Down 1.5 %

Shares of NASDAQ GALT traded down $0.04 during mid-day trading on Monday, reaching $2.63. The company had a trading volume of 62,997 shares, compared to its average volume of 145,262. The firm has a 50 day simple moving average of $2.59 and a two-hundred day simple moving average of $2.74. The stock has a market cap of $163.45 million, a P/E ratio of -3.61 and a beta of 0.61. Galectin Therapeutics Inc. has a 52-week low of $1.55 and a 52-week high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). On average, equities analysts expect that Galectin Therapeutics Inc. will post -0.79 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research report on Friday, August 16th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.